This week, Intellia director, RNA technologies, Weijun Chen, Ph.D., will be presenting at @HansonWade’s 5th mRNA-Based Therapeutics Summit in Boston on July 23 at 1:15 p.m. ET. Learn more about Intellia’s approach to #geneediting:

Big thank you to @US_HAEA for hosting a great conference and those who visited our booth. We appreciated all the insightful conversations and highlighting our progress. Until next time!

We’re looking forward to the 2025 @US_HAEA National Summit this weekend in Baltimore. HCPs: Intellia will present three posters from our #hereditaryangioedema program on Friday, July 11. See you there! #USHAEANationalSummit #HAE

We’re excited to share Intellia will present positive three-year data from our Phase 1 trial in #hereditaryangioedema at today’s @EAACI_HQ Congress and that our global Phase 3 HAELO trial has concluded screening ahead of schedule. Read the press release:

Tomorrow, Intellia Senior Director, Yong Zhang, Ph.D., will take the stage at the 7th Allogeneic Cell Therapies Summit in Boston, where he will discuss Intellia’s allogeneic platform as an approach to #celltherapy.

Our #HAE team is off to Budapest for the C1-Inhibitor Deficiency & Angioedema Workshop. HCPs: tune into our oral and poster presentations this weekend about our research and Phase 3 HAELO study design for #hereditaryangioedema.

We are excited about this new @American_Heart initiative and look forward to supporting continued progress on ATTR-CM. Learn more: . #ATTR #transthyretinamyloidosis.

Members from Intellia management will be at the RBC Capital Markets (@rbccm) Global Healthcare Conference in New York. We look forward to connecting and sharing our vision for the future. $NTLA

Intellia’s SVP, Technical Operations, Kristy Wood, Ph.D., will be delivering a keynote at TIDES (@TIDESInforma) at 10:15 a.m. PT today, titled: Realizing the Promise of #CRISPR Therapies. Join us as we dive into all things about Intellia and #geneediting.

Intellia announces positive two-year follow-up data from its ongoing Phase 1 study in #ATTR with polyneuropathy at the 2025 @PNSociety1 Annual Meeting in Edinburgh (. HCPs: be sure to catch our oral and poster presentation and stop by our booth to meet our

At Intellia, our commitment to the patient community runs deep. This #HAEDay we honor the strength, resilience and stories of those living with #hereditaryangioedema. Together, we can raise awareness and advocate for a better and brighter future. Here are some of our favorite

Intellia is looking forward to attending the HFA/@escardio annual Heart Failure Congress in Belgrade, Serbia. HCPs: tune into our presentation about our approach in hereditary & wild-type #ATTR with cardiomyopathy on May 17: . #HeartFailure2025

This week, Intellia will be in Las Vegas at the @BankofAmerica Securities Healthcare Conference. Join us as our Chief Financial Officer, Ed Dulac, takes part in a fireside chat:

$NTLA announces recent company progress and first quarter financial results. Read more:

This weekend, the Intellia team will be in Las Vegas at the Consortium of Independent Immunology Clinics (CIIC) Spring Conference presenting a poster about our HAELO Phase 3 Trial Design for #hereditaryangioedema. Be sure to stop by our booth to learn more about Intellia.

$NTLA #ATTR Milestone: The first patient has been dosed in Intellia’s Phase 3 MAGNITUDE-2 study of nexiguran ziclumeran (nex-z) for #ATTR with polyneuropathy: #CRISPR #GeneEditing

This weekend, members from the Intellia team will be at the American College of Cardiology (@ACCinTouch) Conference in Chicago. Come visit us at Booth 3052 to learn more about Intellia. #ACC25

$NTLA News: @US_FDA grants Intellia Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z) for the treatment of #ATTR #amyloidosis with cardiomyopathy.